Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04912921 · ClinicalTrials.gov registry record · NA
Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19
A NA study, sponsored by Arizona State University.
- Completed
- Registry status
- NA
- Development phase
- 115
- Enrollment target
NCT04912921 is a NA study that has completed, run by Arizona State University. The registered enrollment target is 115 participants.
The verdict
NCT04912921, a NA study, has completed, sponsored by Arizona State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 115 participants
- Enrollment target
Study Summary
Two randomized controlled trials will be conducted to examine the effect of a food supplement on proinflammatory cytokines and biomarkers in an adult population recently diagnosed with COVID-19 who are asymptomatic or experiencing only mild symptoms. The supplement, palmitoylethanolamide (PEA), is marketed under the trademarked product with increased bioavailability and format versatility: Levagen+™ (Gencor Pacific Limited, Irvine, CA). The supplement curcumin is marketed under the trademarked product with increased bioavailability: HydroCurc (Gencor Pacific Limited, Irvine, CA)
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Curcumin
- DIETARY_SUPPLEMENT palmitoylethanolamide
- DIETARY_SUPPLEMENT Control (microcrystalline cellulose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2022-05-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04912921
The ClinicalTrials.gov registry entry for NCT04912921 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arizona State University, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04912921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04912921 about?
NCT04912921 is a clinical study titled "Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19". Two randomized controlled trials will be conducted to examine the effect of a food supplement on proinflammatory cytokines and biomarkers in an adult population recently diagnosed with COVID-19 who are asymptomatic or experiencing only mild symptoms. The supplement, palmitoylethanolamide (PEA), is m...
What is the current status of trial NCT04912921?
This trial is currently completed. It is a NA study. The enrollment target is 115 participants. The study started on 2020-10-20. Estimated completion is 2022-05-15.
What interventions are being tested in trial NCT04912921?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Curcumin (DIETARY_SUPPLEMENT), palmitoylethanolamide (DIETARY_SUPPLEMENT), Control (microcrystalline cellulose) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04912921?
This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.